<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01184599</url>
  </required_header>
  <id_info>
    <org_study_id>OCGH-746</org_study_id>
    <nct_id>NCT01184599</nct_id>
  </id_info>
  <brief_title>A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kagawa University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kagawa University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of aliskiren, a novel direct rennin
      inhibitor, on renal function and progress of renal disease in hypertensive patients with IgA
      nephropathy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal function (Creatinine clearance)</measure>
    <time_frame>One year (every 6 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary protein</measure>
    <time_frame>One year (every 6 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary angiotensinogen</measure>
    <time_frame>One year (every 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary type 4 collagen</measure>
    <time_frame>One year (every 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Transforming growth factor-beta</measure>
    <time_frame>One year (every 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-sensitivity C-reactive protein</measure>
    <time_frame>One year (every 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Rennin Activity</measure>
    <time_frame>One year (every 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aldosterone</measure>
    <time_frame>One year (every 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asymmetric dimethylarginine</measure>
    <time_frame>One year (every 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Advanced glycation end product</measure>
    <time_frame>One year (every 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Pro)renin receptor</measure>
    <time_frame>One year (every 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress</measure>
    <time_frame>One year (every 12 months)</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glomerulonephritis, IGA</condition>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aliskiren</intervention_name>
    <description>150 mg/day p.o.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IgA nephropathy confirmed by renal biopsy

          -  Hypertension (&lt;= 125/75 mmHg)

        Exclusion Criteria:

          -  Patients who have been treated with angiotensin type 1 receptor blocker or
             angiotensin-converting enzyme inhibitor within 4 weeks

          -  Severe hypertension (&lt;= 180/110 mmHg) or secondary hypertension

          -  Patients with history of allergy or adverse effect for aliskiren

          -  Renal dysfunction (estimated Glomerular Filtration Rate &lt; 60 mL/min/1.73m2)

          -  Pregnancy

          -  Patient treated with cyclosporine

          -  Hyperkalemia (serum potassium &gt;= 5.6 mmol/L)

          -  Autoimmune disease including systemic lupus erythematosus

          -  Patients inadequate for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masahito Imanishi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osaka City General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Masahito Imanishi</last_name>
    <phone>+81-6-6929-1221</phone>
    <email>masachan@msic.med.osaka-cu.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hirofumi Hitomi</last_name>
    <phone>+81-87-891-2125</phone>
    <email>hitomi@kms.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kurume University, School of Medicine</name>
      <address>
        <city>Fukuoka</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine, Osaka City General Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masahito Imanishi</last_name>
      <phone>+81-6-6929-1221</phone>
      <email>masachan@msic.med.osaka-cu.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Masahito Imanishi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohno memorial Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>550-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kinki University, Faculty of Medicine</name>
      <address>
        <city>Osaka</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2010</study_first_submitted>
  <study_first_submitted_qc>August 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2010</study_first_posted>
  <last_update_submitted>June 23, 2011</last_update_submitted>
  <last_update_submitted_qc>June 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Hirofumi Hitomi</name_title>
    <organization>Kagawa University, Faculty of Medicine</organization>
  </responsible_party>
  <keyword>Aliskiren</keyword>
  <keyword>Albuminuria</keyword>
  <keyword>Angiotensinogen</keyword>
  <keyword>collagen type IV</keyword>
  <keyword>Transforming Growth Factor beta</keyword>
  <keyword>aldosterone</keyword>
  <keyword>renin</keyword>
  <keyword>prorenin receptor</keyword>
  <keyword>des-angiotensin I renin substrate</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>advanced glycosylation end-product receptor</keyword>
  <keyword>N,N-dimethylarginine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

